Although an increasing number of clinical trials have tested the efficacy of PD-1/PD-L1 antibodies combined with epigenetic agents based on HDACi treatment of patients with multiple cancer types (Pan and Zheng, 2020), there is no report on the combination therapy of PD-1 and HDACi using in maintenance therapy of T-ALL. This evidence concerns the gene PDCD1 and cancer.